UnknownNot applicableNCT04545788

Randomized Controlled Multi-center Short Course Treatment for Rifampicin Resistant Tuberculosis

Studying Tuberculosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Beijing Chest Hospital
Principal Investigator
NAIHUI CHU, Doctor
Beijing Chest Hospital affiliated to Capital Medical University
Intervention
Total oral short-term therapy that includes linezolid, bedaquiline and/or cycloserine.(drug)
Enrollment
200 enrolled
Eligibility
18-65 years · All sexes
Timeline
2020 – 2022

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04545788 on ClinicalTrials.gov

Other trials for Tuberculosis

Additional recruiting or active studies for the same condition.

See all trials for Tuberculosis →

← Back to all trials